[Treatment of advanced ovarian cancer with cis-dichlorodiammine platinum (CDDP) as single agent or cddp in combination with adriamycin (ADM)].
Twenty-five patients with advanced ovarian cancer were treated with Cis-dichlorodiammneplatinum (CD-DP) 50 mg/m2 as single agent or CDDP 50 mg/m2 in combination with adriamycin (ADM) 50 mg/m2. Both CDDP and CDDP-ADM combination were administered intravenously. Thirteen patients received CDDP alone and twelve patients received CDDP-ADM combination. The single agent activity of CDDP produced a complete response (CR) of 23.1% and a partial response of 15.4% with an overall response rate of 38.5%. The combination of CDDP and ADM gave a response of 58.3% (CR 25.0%, PR 33.3%). Thus, the combination of CDDP and ADM produced a response rate superior to that of CDDP alone. These clinical findings were supported by our investigation of novel experimental therapies in 7, 12 dimethylbenz (a) anthracene induced rat ovarian cancer.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002945:Cisplatin / Q000008:administration & dosage*; D003536:Cystadenocarcinoma / Q000188:drug therapy; D004317:Doxorubicin / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D010051:Ovarian Neoplasms / Q000188:drug therapy*
D004317:Doxorubicin; D002945:Cisplatin